Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. E.T. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of the Apogee Therapeutics website.
Apogee Therapeutics (Nasdaq: APGE) ha annunciato la sua prossima partecipazione alla Guggenheim SMID Cap Biotech Conference. Il team di gestione dell'azienda parteciperà a una chiacchierata informale prevista per mercoledì 5 febbraio 2025, alle 13:00 E.T.. Le parti interessate possono accedere sia alla versione live che a quella registrata della presentazione tramite la pagina News & Events nella sezione Investitori del sito web di Apogee Therapeutics.
Apogee Therapeutics (Nasdaq: APGE) ha anunciado su próxima participación en la Guggenheim SMID Cap Biotech Conference. El equipo de gestión de la empresa estará involucrado en una charla informal programada para miércoles 5 de febrero de 2025, a la 1:00 p.m. E.T.. Las partes interesadas pueden acceder tanto a la versión en vivo como a la grabada de la presentación a través de la página de Noticias y Eventos en la sección de Inversores del sitio web de Apogee Therapeutics.
Apogee Therapeutics (Nasdaq: APGE)는 Guggenheim SMID Cap Biotech Conference에 참여할 것이라고 발표했습니다. 회사의 경영팀은 2025년 2월 5일 수요일, 오후 1시 E.T.에 예정된 대화에 참여할 것입니다. 관심 있는 분들은 Apogee Therapeutics 웹사이트의 투자자 섹션 내 뉴스 및 이벤트 페이지를 통해 실시간 및 녹화된 발표를 모두 이용할 수 있습니다.
Apogee Therapeutics (Nasdaq: APGE) a annoncé sa prochaine participation à la Guggenheim SMID Cap Biotech Conference. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour mercredi 5 février 2025, à 13h00 E.T.. Les parties intéressées peuvent accéder à la fois à la version en direct et à la version archivée de la présentation via la page News & Events dans la section Investisseurs du site web de Apogee Therapeutics.
Apogee Therapeutics (Nasdaq: APGE) hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference angekündigt. Das Management-Team des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 5. Februar 2025, um 13:00 Uhr E.T. angesetzt ist. Interessierte Parteien können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die News- und Veranstaltungsseite im Investorenbereich der Website von Apogee Therapeutics abrufen.
- None.
- None.
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://www.apogeetherapeutics.com/.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Apogee Therapeutics' (APGE) Guggenheim Conference presentation?
What type of presentation will APGE deliver at the Guggenheim SMID Cap Biotech Conference?
Will there be a replay available of APGE's Guggenheim Conference presentation?
